Neil L Berinstein

USPTO Granted Patents = 12 (Patent Applications = 9)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 37(Granted Patents)

Company Filing History:

Immunovaccine Technologies Inc.

patents

1 out of 525

Ludwig Institute for Cancer Research Limited

patents

where one patent can have more than one assignee

Years Active: 2010-2020

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10729766 - Method for improving the efficacy of a survivin vaccine in the treatment of cancer (2020-08-04),

2. 10022441 - Method for improving the efficacy of a survivin vaccine in the treatment of cancer (2018-07-17),

3. 8946174 - Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer (2015-02-03),

4. 8911991 - Multi-antigen vectors of melanoma (2014-12-16),

5. 8802383 - Monoclonal antibodies and uses thereof (2014-08-12),

6. 8361706 - Monoclonal antibodies and uses thereof (2013-01-29),

7. 8207314 - Tumor antigens for prevention and/or treatment of cancer (2012-06-26),

8. 8021664 - Tumor antigens Bfa5 for prevention and/or treatment of cancer (2011-09-20),

9. 8017590 - Method of inducing and/or enhancing an immune response to tumor antigens (2011-09-13),

10. 7851213 - Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer (2010-12-14),

11. 7851212 - Immunogenic polypeptides encoded by MAGE minigenes and uses thereof (2010-12-14),

12. 7790857 - Monoclonal antibodies and uses thereof (2010-09-07),

Title: Neil L. Berinstein: Pioneering Innovations in Cancer Treatment

Introduction:

Neil L. Berinstein, a prominent inventor based in Toronto, Canada, has made significant contributions to the field of cancer treatment with his groundbreaking inventions. With a total of 12 patents to his name, Berinstein's work focuses on improving the efficacy of vaccines in combating cancer.

Latest Patents:

Berinstein's latest patents include a method for enhancing the effectiveness of a survivin vaccine in cancer treatment. This innovative approach involves administering specific agents that interfere with DNA replication before vaccination with the survivin vaccine, leading to enhanced treatment outcomes. The compositions developed as part of these methods show great promise in revolutionizing cancer therapies.

Career Highlights:

Throughout his career, Neil L. Berinstein has collaborated with renowned companies such as Sanofi Pasteur Inc. and Immunovaccine Technologies Inc. These partnerships have allowed him to leverage his inventive prowess and drive towards developing novel solutions for the medical community. Berinstein's work has garnered attention for its potential to reshape the landscape of cancer treatment.

Collaborations:

In his quest for innovative solutions, Neil L. Berinstein has collaborated with accomplished peers such as Corey Lovitt and Laszlo Radvanyi. These collaborations have fostered an environment of shared knowledge and creativity, leading to the successful development of cutting-edge technologies in the fight against cancer. Berinstein's ability to collaborate effectively highlights his commitment to advancing the field of medical science.

Conclusion:

Neil L. Berinstein's dedication to advancing cancer treatment through innovation and collaboration is truly commendable. His inventive spirit and strategic partnerships have laid the foundation for groundbreaking advancements in the field. As he continues to push the boundaries of medical research, Berinstein's legacy as a pioneering inventor in the fight against cancer is set to endure and inspire future generations of innovators.

This text is generated by artificial intelligence and may not be accurate.